Articles published by Novaliq

Novaliq Receives FDA IND Clearance to Advance NOV05 in a Phase II Clinical Trial in Non-infectious Anterior Uveitis

January 26, 2026

From Novaliq

Via Business Wire

Breakthrough in Ophthalmology! Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as First Treatment for Dry Eye Disease Associated with MGD

July 08, 2025

From Novaliq

Via Business Wire

Novaliq and Laboratoires Théa Announce Partnership and EU Approval for Vevizye® (Ciclosporin 0.1% Eye Drops Solution)

October 02, 2024

From Novaliq

Via Business Wire

Novaliq Receives Positive CHMP Opinion for Vevizye® in Dry Eye Disease

July 29, 2024

From Novaliq

Via Business Wire

European Medicines Agency Accepts Novaliq’s Marketing Authorization Application for CyclASol® (ciclosporin ophthalmic solution) 0.1% for the Treatment of Dry Eye Disease

August 24, 2023

From Novaliq

Via Business Wire

Novaliq Announces Presentation of New Scientific Data on CyclASol® 0.1% (Cyclosporine Ophthalmic Solution) at the American Society of Cataract and Refractive Surgery Annual Meeting

May 02, 2023

From Novaliq

Via Business Wire

Novaliq Announces Publication of Second Pivotal Phase 3 Trial Data on CyclASol 0.1% (Cyclosporine Ophthalmic Solution) in JAMA Ophthalmology

April 12, 2023

From Novaliq

Via Business Wire

Novaliq Plans to File a Markting Authorisation Application for CyclASol® in the E.U. for the Treatment of Dry Eye Disease in July 2023

February 08, 2023

From Novaliq

Via Business Wire

Novaliq Announces FDA Acceptance of the New Drug Application for CyclASol® for the Treatment of Dry Eye Disease

October 24, 2022

From Novaliq

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.